

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.


The claims have been amended to delete multiple dependencies and to place the application into better form for examination. Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

BY 
James M. Slattery, #28,380

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

JMS/cqc
3868-0109P

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

(Rev. 02/21/02)

20250220 00469001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The title has been amended as follows:

PHARMACEUTICAL PREPARATION CONTAINING NANOSOL

The claims have been amended as follows:

4. (Amended) Solid pharmaceutical preparation according to [any one of the preceding claims]claim 1, characterized in that the active substance and the chitosan derivative are present in the nanosol in almost isoionic state.

5. (Amended) Solid pharmaceutical preparation according to [any one of the preceding claims]claim 1, characterized in that the active substance is present in the nanosol in colloidal or in nanoparticulate form.

6. (Amended) Solid pharmaceutical preparation according to [any one of the preceding claims]claim 1, characterized in that the active substance is poorly soluble.

7. (Amended) Solid pharmaceutical preparation according to [any one of the preceding claims]claim 1, characterized in that it contains a further polymeric carrier substance apart from the chitosan derivative.

8. (Amended) Use of a pharmaceutical preparation according to [any one of the preceding claims]claim 1 for the production of a medicinal product.

10. (Amended) Use of a pharmaceutical preparation according to [any one of Claims 8 or 9]claim 8 for the production of a medicinal product that is administered as a powder, granulate, tablet or capsule.

11. (Amended) Use of a pharmaceutical preparation according to [any one of Claims 8 to 10]claim 8 for the production of a medicinal product which, for the purpose of administration, is dissolved or redispersed in a liquid.

12. (Amended) Use of a pharmaceutical preparation according to [any one of Claims 8 to 11]claim 8 for the production of a medicinal product having controlled active substance release.

13. (Amended) Use of a pharmaceutical preparation according to [any one of Claims 1 to 7]claim 1 for the production of a diagnostic agent.

14. (Amended) Process for the production of a pharmaceutical preparation according to [any one of Claims 1 to 7]claim 1, characterized in that

- a) a chitosan derivative is selected according to the type and relative number of its charged groups and in coordination with the type and relative number of the charged groups of the active substance such that at a certain pH value an isoionic state or charge equalization between active substance and carrier can be achieved in the preparation,
- b) an aqueous sol containing the active substance is prepared from the chitosan derivative,
- c) the pH value of the aqueous sol is adjusted such that an isoionic state results, possibly with colloidal or nano-scale active substance particles precipitating, and
- d) the thus-adjusted aqueous sol is dried.

(Rev. 11/13/01)

20250204 10:06:40